Uterine Fibroids

Key clinical point: A prognostic index (PI) model was effective in predicting the recurrence of uterine fibroids following myomectomy.

Major finding: The high- and intermediate-risk groups had a 4.55- and 2.81-fold greater recurrence risk, respectively, for uterine fibroids than the low-risk group.

Study details: A retrospective multicenter study of 725 women who underwent myomectomy was used to develop the PI model. The PI formula was 1.5 (if 3-5 fibroids) or 2 (if >5 fibroids)+1 (if residue)+1 (if not submucosal)+1 (if combined endometriosis). Patients were characterized into low, intermediate, and high risks by PI cut-off values 1.25 and 3.75.

Disclosures: The study was supported by a grant from the Applied Basic Research Programs of Science and Technology Department of Sichuan Province. The authors declared no conflict of interests.

Source: Ming X et al. PLoS One. 2021 Jul 1. doi: 10.1371/journal.pone.0254142.

Key clinical point: A prognostic index (PI) model was effective in predicting the recurrence of uterine fibroids following myomectomy.

Major finding: The high- and intermediate-risk groups had a 4.55- and 2.81-fold greater recurrence risk, respectively, for uterine fibroids than the low-risk group.

Study details: A retrospective multicenter study of 725 women who underwent myomectomy was used to develop the PI model. The PI formula was 1.5 (if 3-5 fibroids) or 2 (if >5 fibroids)+1 (if residue)+1 (if not submucosal)+1 (if combined endometriosis). Patients were characterized into low, intermediate, and high risks by PI cut-off values 1.25 and 3.75.

Disclosures: The study was supported by a grant from the Applied Basic Research Programs of Science and Technology Department of Sichuan Province. The authors declared no conflict of interests.

Source: Ming X et al. PLoS One. 2021 Jul 1. doi: 10.1371/journal.pone.0254142.

Key clinical point: A prognostic index (PI) model was effective in predicting the recurrence of uterine fibroids following myomectomy.

Major finding: The high- and intermediate-risk groups had a 4.55- and 2.81-fold greater recurrence risk, respectively, for uterine fibroids than the low-risk group.

Study details: A retrospective multicenter study of 725 women who underwent myomectomy was used to develop the PI model. The PI formula was 1.5 (if 3-5 fibroids) or 2 (if >5 fibroids)+1 (if residue)+1 (if not submucosal)+1 (if combined endometriosis). Patients were characterized into low, intermediate, and high risks by PI cut-off values 1.25 and 3.75.

Disclosures: The study was supported by a grant from the Applied Basic Research Programs of Science and Technology Department of Sichuan Province. The authors declared no conflict of interests.

Source: Ming X et al. PLoS One. 2021 Jul 1. doi: 10.1371/journal.pone.0254142.

Key clinical point: High-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids demonstrated superior outcomes in terms of symptomatic relief, improvement in quality of life (QoL), recovery, and complications compared with surgery.

Major finding: Compared with the surgery group, the HIFU group demonstrated a greater reduction in uterine fibroid severity score at 6- and 12-month follow-up (P less than .05), greater increase in QoL score at 6- and 12-month follow-up (P < .05), and shorter duration of hospital stay and return to work (P less than .05). Differences in adverse events, symptom recurrence, reintervention, and pregnancy between the groups were not significant (P greater than .05).

Study details: The data come from a meta-analysis of 10 studies involving 4,450 women.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Liu L et al. Eur Radiol. 2021 Aug 1. doi: 10.1007/s00330-021-08156-6.

Key clinical point: High-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids demonstrated superior outcomes in terms of symptomatic relief, improvement in quality of life (QoL), recovery, and complications compared with surgery.

Major finding: Compared with the surgery group, the HIFU group demonstrated a greater reduction in uterine fibroid severity score at 6- and 12-month follow-up (P less than .05), greater increase in QoL score at 6- and 12-month follow-up (P < .05), and shorter duration of hospital stay and return to work (P less than .05). Differences in adverse events, symptom recurrence, reintervention, and pregnancy between the groups were not significant (P greater than .05).

Study details: The data come from a meta-analysis of 10 studies involving 4,450 women.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Liu L et al. Eur Radiol. 2021 Aug 1. doi: 10.1007/s00330-021-08156-6.

Key clinical point: High-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids demonstrated superior outcomes in terms of symptomatic relief, improvement in quality of life (QoL), recovery, and complications compared with surgery.

Major finding: Compared with the surgery group, the HIFU group demonstrated a greater reduction in uterine fibroid severity score at 6- and 12-month follow-up (P less than .05), greater increase in QoL score at 6- and 12-month follow-up (P < .05), and shorter duration of hospital stay and return to work (P less than .05). Differences in adverse events, symptom recurrence, reintervention, and pregnancy between the groups were not significant (P greater than .05).

Study details: The data come from a meta-analysis of 10 studies involving 4,450 women.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Liu L et al. Eur Radiol. 2021 Aug 1. doi: 10.1007/s00330-021-08156-6.

Key clinical point: Three-dimensional (3D) laparoscopic myomectomy for uterine fibroids has no additional surgical benefit compared with conventional two-dimensional (2D) laparoscopic myomectomy.

Major finding: There were no significant differences between the 3D and 2D groups in terms of operative blood loss (P = .421), change in serum hemoglobin levels (P = .553), and operative time (P = .344).

Study details: In a randomized controlled trial, 64 patients with symptomatic uterine fibroids were assigned either to 3D (n=32) or 2D (n=32) laparoscopic myomectomy.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Song T and Kang DY. Eur J Obstet Gynecol Reprod Biol. 2021 Jul 23. doi: 10.1016/j.ejogrb.2021.07.036.

Key clinical point: Three-dimensional (3D) laparoscopic myomectomy for uterine fibroids has no additional surgical benefit compared with conventional two-dimensional (2D) laparoscopic myomectomy.

Major finding: There were no significant differences between the 3D and 2D groups in terms of operative blood loss (P = .421), change in serum hemoglobin levels (P = .553), and operative time (P = .344).

Study details: In a randomized controlled trial, 64 patients with symptomatic uterine fibroids were assigned either to 3D (n=32) or 2D (n=32) laparoscopic myomectomy.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Song T and Kang DY. Eur J Obstet Gynecol Reprod Biol. 2021 Jul 23. doi: 10.1016/j.ejogrb.2021.07.036.

Key clinical point: Three-dimensional (3D) laparoscopic myomectomy for uterine fibroids has no additional surgical benefit compared with conventional two-dimensional (2D) laparoscopic myomectomy.

Major finding: There were no significant differences between the 3D and 2D groups in terms of operative blood loss (P = .421), change in serum hemoglobin levels (P = .553), and operative time (P = .344).

Study details: In a randomized controlled trial, 64 patients with symptomatic uterine fibroids were assigned either to 3D (n=32) or 2D (n=32) laparoscopic myomectomy.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Song T and Kang DY. Eur J Obstet Gynecol Reprod Biol. 2021 Jul 23. doi: 10.1016/j.ejogrb.2021.07.036.

Key clinical point: Women with uterine fibroids, especially those with pain symptoms or who have had a hysterectomy, may have an increased risk for certain mental health outcomes.

Major finding: After adjusting for confounders, women with uterine fibroids vs those without had higher rates of depression (hazard ratio [HR], 1.12; 95% confidence interval [CI], 1.10-1.13), anxiety (HR, 1.12; 95% CI, 1.10-1.13), and self-directed violence (HR, 1.46; 95% CI, 1.29-1.64). These associations were more pronounced in women experiencing pain symptoms and in those who underwent a hysterectomy.

Study details: The data come from a cohort study of 313,754 women aged 18-50 years with diagnosed uterine fibroids who were matched to 627,539 women without uterine fibroids.

Disclosures: The research was funded by AbbVie, and Aetion received funding for conducting the study. SE Chiuve, C Huisingh, and C Owens are employees of AbbVie receiving stock and/or stock options. N Petruski-Ivleva was an employee of Aetion when the study was being conducted and may hold stock options at Aetion. W Kuohung and LA Wise received consultancy fees from AbbVie, but did not receive payment for authorship.

Source: Chiuve SE et al. J Epidemiol Community Health. 2021 Jul 22. doi: 10.1136/jech-2020-214565.

Key clinical point: Women with uterine fibroids, especially those with pain symptoms or who have had a hysterectomy, may have an increased risk for certain mental health outcomes.

Major finding: After adjusting for confounders, women with uterine fibroids vs those without had higher rates of depression (hazard ratio [HR], 1.12; 95% confidence interval [CI], 1.10-1.13), anxiety (HR, 1.12; 95% CI, 1.10-1.13), and self-directed violence (HR, 1.46; 95% CI, 1.29-1.64). These associations were more pronounced in women experiencing pain symptoms and in those who underwent a hysterectomy.

Study details: The data come from a cohort study of 313,754 women aged 18-50 years with diagnosed uterine fibroids who were matched to 627,539 women without uterine fibroids.

Disclosures: The research was funded by AbbVie, and Aetion received funding for conducting the study. SE Chiuve, C Huisingh, and C Owens are employees of AbbVie receiving stock and/or stock options. N Petruski-Ivleva was an employee of Aetion when the study was being conducted and may hold stock options at Aetion. W Kuohung and LA Wise received consultancy fees from AbbVie, but did not receive payment for authorship.

Source: Chiuve SE et al. J Epidemiol Community Health. 2021 Jul 22. doi: 10.1136/jech-2020-214565.

Key clinical point: Women with uterine fibroids, especially those with pain symptoms or who have had a hysterectomy, may have an increased risk for certain mental health outcomes.

Major finding: After adjusting for confounders, women with uterine fibroids vs those without had higher rates of depression (hazard ratio [HR], 1.12; 95% confidence interval [CI], 1.10-1.13), anxiety (HR, 1.12; 95% CI, 1.10-1.13), and self-directed violence (HR, 1.46; 95% CI, 1.29-1.64). These associations were more pronounced in women experiencing pain symptoms and in those who underwent a hysterectomy.

Study details: The data come from a cohort study of 313,754 women aged 18-50 years with diagnosed uterine fibroids who were matched to 627,539 women without uterine fibroids.

Disclosures: The research was funded by AbbVie, and Aetion received funding for conducting the study. SE Chiuve, C Huisingh, and C Owens are employees of AbbVie receiving stock and/or stock options. N Petruski-Ivleva was an employee of Aetion when the study was being conducted and may hold stock options at Aetion. W Kuohung and LA Wise received consultancy fees from AbbVie, but did not receive payment for authorship.

Source: Chiuve SE et al. J Epidemiol Community Health. 2021 Jul 22. doi: 10.1136/jech-2020-214565.

Rana et al published a cost-effectiveness analysis in the British Journal of Obstetrics and Gynecology that evaluated the cost-effectiveness of uterine artery embolization (UAE) and myomectomy for women with symptomatic uterine fibroids wishing to avoid hysterectomy. The analysis was conducted along the FEMME randomized control trial, that examined the quality of life of menstruating women with symptomatic fibroids experience after treatment with UAE or myomectomy. Over a 2-year time period, UAE was associated with higher mean costs and lower quality-adjusted life years compared with myomectomy. Similar results were observed over the 4-year time period. The authors concluded that myomectomy is a cost-effective option for the treatment of uterine fibroids.

A third study by Moor et al evaluated the impact of herpes simplex type 2 (HSV-2) infection on incidence and growth of ultrasound-diagnosed uterine fibroids in a large group of African American women. As reproductive tract infections have long been suspected as risk factors for fibroid development, this is a key study. In this prospective study analyzing data from the Study of Environment, Lifestyle and a large cohort of 25-35 year-old African American women with uterine fibroids were monitored by ultrasound over a 5-year period. A key finding was that fibroid HSV-2 positive status was not associated with fibroid incidence.

Rana et al published a cost-effectiveness analysis in the British Journal of Obstetrics and Gynecology that evaluated the cost-effectiveness of uterine artery embolization (UAE) and myomectomy for women with symptomatic uterine fibroids wishing to avoid hysterectomy. The analysis was conducted along the FEMME randomized control trial, that examined the quality of life of menstruating women with symptomatic fibroids experience after treatment with UAE or myomectomy. Over a 2-year time period, UAE was associated with higher mean costs and lower quality-adjusted life years compared with myomectomy. Similar results were observed over the 4-year time period. The authors concluded that myomectomy is a cost-effective option for the treatment of uterine fibroids.

A third study by Moor et al evaluated the impact of herpes simplex type 2 (HSV-2) infection on incidence and growth of ultrasound-diagnosed uterine fibroids in a large group of African American women. As reproductive tract infections have long been suspected as risk factors for fibroid development, this is a key study. In this prospective study analyzing data from the Study of Environment, Lifestyle and a large cohort of 25-35 year-old African American women with uterine fibroids were monitored by ultrasound over a 5-year period. A key finding was that fibroid HSV-2 positive status was not associated with fibroid incidence.

Rana et al published a cost-effectiveness analysis in the British Journal of Obstetrics and Gynecology that evaluated the cost-effectiveness of uterine artery embolization (UAE) and myomectomy for women with symptomatic uterine fibroids wishing to avoid hysterectomy. The analysis was conducted along the FEMME randomized control trial, that examined the quality of life of menstruating women with symptomatic fibroids experience after treatment with UAE or myomectomy. Over a 2-year time period, UAE was associated with higher mean costs and lower quality-adjusted life years compared with myomectomy. Similar results were observed over the 4-year time period. The authors concluded that myomectomy is a cost-effective option for the treatment of uterine fibroids.

A third study by Moor et al evaluated the impact of herpes simplex type 2 (HSV-2) infection on incidence and growth of ultrasound-diagnosed uterine fibroids in a large group of African American women. As reproductive tract infections have long been suspected as risk factors for fibroid development, this is a key study. In this prospective study analyzing data from the Study of Environment, Lifestyle and a large cohort of 25-35 year-old African American women with uterine fibroids were monitored by ultrasound over a 5-year period. A key finding was that fibroid HSV-2 positive status was not associated with fibroid incidence.

Key clinical point: Pituitrin 2 units (2U) for laparoscopic uterine myomectomy could provide a satisfactory surgical field with minimal hemodynamic changes.

Major finding: There were no differences among 2U, 4U, and 6U groups in the surgical condition quality. Pituitrin 2U significantly reduced blood loss vs pituitrin 0U, and increasing the pituitrin dose beyond 2U did not reduce blood loss further.

Study details: In a prospective, double-blind trial, 118 patients undergoing laparoscopic myomectomy were randomly assigned to receive 0U, 2U, 4U, or 6U of pituitrin injected into the myometrium surrounding the myoma.

Disclosures: The study was supported by grants from the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Guo F et al. J Minim Invasive Gynecol. 2021 Jun 17. doi: 10.1016/j.jmig.2021.06.008.

Key clinical point: Pituitrin 2 units (2U) for laparoscopic uterine myomectomy could provide a satisfactory surgical field with minimal hemodynamic changes.

Major finding: There were no differences among 2U, 4U, and 6U groups in the surgical condition quality. Pituitrin 2U significantly reduced blood loss vs pituitrin 0U, and increasing the pituitrin dose beyond 2U did not reduce blood loss further.

Study details: In a prospective, double-blind trial, 118 patients undergoing laparoscopic myomectomy were randomly assigned to receive 0U, 2U, 4U, or 6U of pituitrin injected into the myometrium surrounding the myoma.

Disclosures: The study was supported by grants from the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Guo F et al. J Minim Invasive Gynecol. 2021 Jun 17. doi: 10.1016/j.jmig.2021.06.008.

Key clinical point: Pituitrin 2 units (2U) for laparoscopic uterine myomectomy could provide a satisfactory surgical field with minimal hemodynamic changes.

Major finding: There were no differences among 2U, 4U, and 6U groups in the surgical condition quality. Pituitrin 2U significantly reduced blood loss vs pituitrin 0U, and increasing the pituitrin dose beyond 2U did not reduce blood loss further.

Study details: In a prospective, double-blind trial, 118 patients undergoing laparoscopic myomectomy were randomly assigned to receive 0U, 2U, 4U, or 6U of pituitrin injected into the myometrium surrounding the myoma.

Disclosures: The study was supported by grants from the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Guo F et al. J Minim Invasive Gynecol. 2021 Jun 17. doi: 10.1016/j.jmig.2021.06.008.

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.

Key clinical point: Myomectomy is a cost-effective treatment option for uterine fibroids compared with uterine artery embolization (UAE).

Major finding: UAE was associated with higher mean costs (difference, £645; 95% confidence interval [CI], £−1,381 to £2,580) and lower quality-adjusted life years (difference, −0.09; 95% CI, −0.11 to −0.04) vs myomectomy over a 2-year follow-up period. Results were comparable over a 4-year follow-up period.

Study details: The data come from a cost-utility analysis of the FEMME trial. A total of 254 premenopausal women with symptomatic uterine fibroids were randomly assigned to either UAE (n=127) and myomectomy (n=127).

Disclosures: The study was supported by the National Institute of Health Research Health Technology Assessment programme. The authors declared no relevant conflicts of interest.

Source: Rana D et al. BJOG. 2021 May 30. doi: 10.1111/1471-0528.16781.

Key clinical point: Seroprevalence of herpes simplex virus (HSV)-2 was not associated with incidence and growth of ultrasound-diagnosed uterine fibroids in young African-American women.

Major finding: HSV-2 seropositivity had no significant association with fibroid incidence (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.69-1.12) or growth 3.1% (95% CI, −5.8% to 13.0%).

Study details: A cohort study examined the associations of HSV-2 with fibroid incidence and growth among African-American women aged 23-35 years who underwent ultrasound fibroid screening.

Disclosures: This study was supported by the Intramural Research Program of the National Institute of Health, the National Institute of Environmental Health Sciences, and the American Recovery and Reinvestment Act funds designated for the National Institute of Health Research. The authors declared no conflicts of interest.

Source: Moore KR et al. Am J Epidemiol. 2021 May 27. doi: 10.1093/aje/kwab160.

Key clinical point: Seroprevalence of herpes simplex virus (HSV)-2 was not associated with incidence and growth of ultrasound-diagnosed uterine fibroids in young African-American women.

Major finding: HSV-2 seropositivity had no significant association with fibroid incidence (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.69-1.12) or growth 3.1% (95% CI, −5.8% to 13.0%).

Study details: A cohort study examined the associations of HSV-2 with fibroid incidence and growth among African-American women aged 23-35 years who underwent ultrasound fibroid screening.

Disclosures: This study was supported by the Intramural Research Program of the National Institute of Health, the National Institute of Environmental Health Sciences, and the American Recovery and Reinvestment Act funds designated for the National Institute of Health Research. The authors declared no conflicts of interest.

Source: Moore KR et al. Am J Epidemiol. 2021 May 27. doi: 10.1093/aje/kwab160.

Key clinical point: Seroprevalence of herpes simplex virus (HSV)-2 was not associated with incidence and growth of ultrasound-diagnosed uterine fibroids in young African-American women.

Major finding: HSV-2 seropositivity had no significant association with fibroid incidence (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.69-1.12) or growth 3.1% (95% CI, −5.8% to 13.0%).

Study details: A cohort study examined the associations of HSV-2 with fibroid incidence and growth among African-American women aged 23-35 years who underwent ultrasound fibroid screening.

Disclosures: This study was supported by the Intramural Research Program of the National Institute of Health, the National Institute of Environmental Health Sciences, and the American Recovery and Reinvestment Act funds designated for the National Institute of Health Research. The authors declared no conflicts of interest.

Source: Moore KR et al. Am J Epidemiol. 2021 May 27. doi: 10.1093/aje/kwab160.

Key clinical point: A fifth of clinically stable patients receiving intermittent ulipristal acetate (UPA) treatment for uterine fibroids needed surgery after it was suspended by the European Medicines Agency in March 2020, because of safety concerns.

Major finding: Following the suspension of UPA, 20% of patients receiving intermittent UPA needed surgery and 80% needed other medical treatments.

Study details: The data come from an analysis of 85 women who received intermittent UPA treatment until it was suspended in March 2020.

Disclosures: No funding information was available. The authors declared no conflicts of interest.

Source: Nicolás I et al. Gynecol Endocrinol. 2021 May 28. doi: 10.1080/09513590.2021.1929152.

Key clinical point: A fifth of clinically stable patients receiving intermittent ulipristal acetate (UPA) treatment for uterine fibroids needed surgery after it was suspended by the European Medicines Agency in March 2020, because of safety concerns.

Major finding: Following the suspension of UPA, 20% of patients receiving intermittent UPA needed surgery and 80% needed other medical treatments.

Study details: The data come from an analysis of 85 women who received intermittent UPA treatment until it was suspended in March 2020.

Disclosures: No funding information was available. The authors declared no conflicts of interest.

Source: Nicolás I et al. Gynecol Endocrinol. 2021 May 28. doi: 10.1080/09513590.2021.1929152.

Key clinical point: A fifth of clinically stable patients receiving intermittent ulipristal acetate (UPA) treatment for uterine fibroids needed surgery after it was suspended by the European Medicines Agency in March 2020, because of safety concerns.

Major finding: Following the suspension of UPA, 20% of patients receiving intermittent UPA needed surgery and 80% needed other medical treatments.

Study details: The data come from an analysis of 85 women who received intermittent UPA treatment until it was suspended in March 2020.

Disclosures: No funding information was available. The authors declared no conflicts of interest.

Source: Nicolás I et al. Gynecol Endocrinol. 2021 May 28. doi: 10.1080/09513590.2021.1929152.

Key clinical point: Application of temporary uterine tourniquet may be effective in reducing perioperative bleeding in patients with multiple, large-sized uterine fibroids in close proximity of vascular structures.

Major finding: The tourniquet applied group vs not applied group had more favorable outcomes in terms of hemoglobin drop (P = .019), hematocrit drop (P = .023), transfusion amount (P = .012), operation time (P = .044), and duration of hospitalization (P = .036).

Study details: The data come from a retrospective study involving 84 patients who underwent abdominal myomectomy and were categorized into 2 groups according to the use (n=36) or nonuse (n=48) of a temporary uterine tourniquet.

Disclosures: The study did not receive any financial support. The authors declared no conflicts of interest.

Source: Akbaba E et al. J Turk Ger Gynecol Assoc. 2021 Jun 8. doi: 10.4274/jtgga.galenos.2021.2020.0242.

Key clinical point: Application of temporary uterine tourniquet may be effective in reducing perioperative bleeding in patients with multiple, large-sized uterine fibroids in close proximity of vascular structures.

Major finding: The tourniquet applied group vs not applied group had more favorable outcomes in terms of hemoglobin drop (P = .019), hematocrit drop (P = .023), transfusion amount (P = .012), operation time (P = .044), and duration of hospitalization (P = .036).

Study details: The data come from a retrospective study involving 84 patients who underwent abdominal myomectomy and were categorized into 2 groups according to the use (n=36) or nonuse (n=48) of a temporary uterine tourniquet.

Disclosures: The study did not receive any financial support. The authors declared no conflicts of interest.

Source: Akbaba E et al. J Turk Ger Gynecol Assoc. 2021 Jun 8. doi: 10.4274/jtgga.galenos.2021.2020.0242.

Key clinical point: Application of temporary uterine tourniquet may be effective in reducing perioperative bleeding in patients with multiple, large-sized uterine fibroids in close proximity of vascular structures.

Major finding: The tourniquet applied group vs not applied group had more favorable outcomes in terms of hemoglobin drop (P = .019), hematocrit drop (P = .023), transfusion amount (P = .012), operation time (P = .044), and duration of hospitalization (P = .036).

Study details: The data come from a retrospective study involving 84 patients who underwent abdominal myomectomy and were categorized into 2 groups according to the use (n=36) or nonuse (n=48) of a temporary uterine tourniquet.

Disclosures: The study did not receive any financial support. The authors declared no conflicts of interest.

Source: Akbaba E et al. J Turk Ger Gynecol Assoc. 2021 Jun 8. doi: 10.4274/jtgga.galenos.2021.2020.0242.